At ARTIDIS AG, we are committed to radically improving health outcomes by harnessing the power of nanotechnology and innovation. ARTIDIS™, our innovative new nanotechnology tool for cancer diagnosis and treatment, seeks to improve people’s lives by dramatically reducing the time it takes to accurately diagnose breast cancer – from a period of days or weeks to as little as three hours —thereby substantially reducing anxiety and time lost. ARTIDIS™ will also improve lives by facilitating personalized treatments, based on precise measurements of the aggressiveness of the cancer and individuals’ specific medical data and histories.
We believe that same-day diagnosis and individually-based treatment are the future of health care. We also believe that medicine should be informed by the very latest discoveries in cutting-edge research. Accordingly, we are working on applications for our technology to the treatment of diseases beyond breast cancer. At ARTIDIS AG, we are committed to innovation and excellence, in order to bring the future of health care to people today.
ARTIDIS™, which stands for “Automated Reliable Tissue Diagnostics,” is an innovative, nanomechanical diagnostic tool that evaluates tissue samples from biopsies in less than three hours. The ARTIDIS™ platform is based on an atomic force microscope that uses a fine, nanometer-scale probe to determine the nanomechanical properties of cells and the extracellular matrix. By providing the nanomechanical profiles of patient biopsy samples, ARTIDIS™ enables doctors to shorten diagnosis time and enables treatment optimization. In addition, we are building ARTIDISNet, a data system that combines access to individualized medical data, detailed and precise information about tissue status and prognosis, and instant access to “big data” from millions of other examples, in order to enable medical professionals to determine the best course of treatment for a particular individual. This innovation will mitigate the risk of both “overtreatment” and “undertreatment.” Harnessing the combined power of big data and accurate diagnostics will mean that doctors will have the best data at their fingertips. Better data means better treatment.
ARTIDIS™ AG was founded in 2014 initially under the name Nuomedis AG as a spin-off from the University of Basel. The company focuses on the development and marketing of the ARTIDIS™ nanotechnology platform that contributes to the development of personalized therapy for cancer patients by improving cancer diagnosis and prognosis.
We Are Hiring
We are hiring software developers. We are looking for people who are passionate about improving lives through the latest innovative health technology. We offer an exciting, fast-paced and collegial work environment that values creativity and innovation. We are committed to bringing patients and medical professionals the very best diagnostic and treatment options possible. If you are interested in joining our team, please contact us at email@example.com.
Marija Plodinec studied physics in Zagreb and received her doctorate in 2010 from the Maurice Müller Institute at the Biozentrum of the University of Basel. She has been instrumental in the development of ARTIDIS™, a device capable of distinguishing benign from malignant tissue. During her many years as a research associate at the Biozentrum of the University of Basel and as a project leader at the University Hospital Basel, she has brought this technology from basic research to the first clinical studies. Dr. Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. She co-founded ARTIDIS™ AG to further develop and market this platform for cancer diagnosis and prognosis. Since November 2017, Dr. Marija Plodinec serves as the CEO of ARTIDIS™ AG and as a Member of its Board of Directors.
Dr. Philipp Oertle studied Nanoscience at the University of Basel and received a PhD in Nanotechnology from the University of Basel in 2016. He is a co-initiator of the ARTIDIS project and co-founder of the company. During his PhD and subsequent Postdoctoral Fellowship, he studied the basic bio-physical principles that regulate the microenvironment of cancer. In two CTI projects and one Nano-tera project, he was also involved in building the ARTIDIS device from its very first version. He is a co-author on patents related to ARTIDIS technology and also contributed to many basic research articles published in peer-reviewed magazines in the fields of mechanobiology and ophthalmology. He joined ARTIDIS in November 2017 as a full-time employee and is responsible for managing the development of the ARTIDIS Medical Device. His primary responsibility is to provide a functional device to conduct multi-centric clinical studies that can receive a CE label and FDA approval.
Tobias Appenzeller has his origins in chemical and pharmaceutical research. As a trained chemistry assistant, he performed chemistry research for an international company and later pharmaceutical research for a Swiss company. During that time, he gained start-up experience by co-founding and managing a beer-delivery service. After studying Nanoscience at the University of Basel, he worked as a Clinical Research Associate at the University Hospital of Basel. In this position, he organized and managed the first ever conducted clinical study on the Atomic Force Microscopy (AFM) Technology in cancer research. He is a co-founder of ARTIDS AG and joined as a Head of Clinical Operations & Quality in November 2017.
Martin Gertsch is an experienced Board Member and Financial Advisor in the life sciences industry. He served as Chief Financial Officer of Acino Holding in 2013 till January 2014. Prior to that, he was Vice President Head of Finance EMEA at Synthes and held Chief Financial Officer and Chief Operating Officer positions at Delenex Therapeutics and ESBATech, two privately held biotech companies. From 2002 to the beginning of 2006, he was Chief Financial Officer of Straumann, which he joined in 1997 as Head of Group Controlling and Reporting. Between 1986 and 1997, Martin was an Audit Engagement Manager at PricewaterhouseCoopers, Basel, Switzerland. Martin is a Swiss-certified fiduciary and Swiss-certified public accountant. He has also completed several executive-level development programs at IMD (the lnternational Institute for Management Development) in Lausanne, Switzerland. He serves as a Board Member of Santhera Pharmaceutical Holding, Evolva Holding and the University Center of Dentistry, Basel (UZB). He is also Chairman of another diagnostic start-up company.
Silvio Inderbitzin has held multiple senior positions in the pharmaceutical industry over the last 20 years. With his origin in pharmaceutical manufacturing, he built a corporate-wide GMP-quality assurance infrastructure as Head of Quality Assurance and was responsible for product release as a Qualified Person in a medium-sized Swiss pharmaceutical company. He was later elected to the position of Technical Director and served on the Corporate Management Team, ultimately joining the Board of Directors and becoming co-owner of the privately-held 450 employee company. Prior to the successful sale of the company, he served as a CEO and was responsible for its foreign subsidiaries. He is an active investor, consultant and Board Member of several life science start-up companies. Dr. Inderbitzin studied Pharmacy at the University of Berne. He holds a PhD in Pharmacology from the University of Zurich/ETH and obtained an Executive MBA from the University of St. Gallen.